HemoClear

In “Guidance on Implementing Patient Blood Management to Improve Global Blood Health Status”, the World Health Organization calls for practical strategies to reduce dependence on donor blood.

The WHO cites HemoClear® as part of the autologous transfusion management toolkit.
The HemoClear gravity-driven blood filter enables high-quality bedside autotransfusion, offering a portable solution for hospitals, emergency response teams, and rural clinics.

🩸 No electricity, no infrastructure, just a system-ready innovation that aligns with WHO’s call for resilient, resource-appropriate blood management.

🌐https://www.hemoclear.com/

Cell Salvage process optimization drives quality

An analysis of 238 centrifugal cell salvage procedures (154 men, 84 women) demonstrated that quality control benchmarks were consistently achieved, reinforcing the reliability of autologous transfusion in surgical care.

Nevertheless, some variability was observed:
🔴Hematocrit targets were not met in 22% of cases
🔴Total protein elimination was insufficient in 8%

Patient-specific factors, such as age, gender, and surgical indication, had minimal impact on these outcomes.

Instead, variability was driven in nonemergency cases, by technical and procedural conditions, such as:
🔵 Low collection volumes
🔵 Excessive dilution with irrigation fluids

Anesthesiologists play a pivotal role in ensuring the quality of autologous transfusion. With real-time awareness, they adapt collection and wash parameters, even in complex or suboptimal surgical conditions, to uphold transfusion standards and protect patient outcomes.

Curious to test microfiltration technology under similar conditions, independent of centrifugal systems?

✉️ Contact us at info@https://bit.ly/419jNT1
🌐 Visit https://bit.ly/419jNT1
📑 Reference: https://bit.ly/4lPn56q

Advancing Intraoperative Blood Management in Spine Surgery

In Adult Spine Deformity (ASD) surgery, where intraoperative blood loss is often significant, cell salvage plays a critical role in reducing reliance on allogenic transfusions and improving perioperative outcomes.

Key clinical and economic advantages include:
✅ Reduction in allogenic transfusion rates by 18–33%
✅ Preservation of 0.3–1 unit of donor blood per patient, when transfusion is still required
✅ Greatest efficacy observed in procedures with blood loss ≥15 mL/kg
✅ Potential cost savings up to $422 per case

Hemoclear introduces a novel solution, a straightforward, single-use microfiltration system that enables broader access to platelet-rich autologous blood reinfusion. By eliminating the complexity of conventional systems, Hemoclear offers an adaptable and cost-effective approach to intraoperative blood recovery.

Learn more: [email protected] | 🌐 https://bit.ly/3Ck6OB9